Date post: | 09-Jan-2017 |
Category: |
Health & Medicine |
Upload: | dfsimedia |
View: | 440 times |
Download: | 4 times |
THE DIABETIC FOOT: AN OVERVIEW September 2004
Andrew J M Boulton MD, DSc (Hon), FRCPProfessor of Medicine, University of ManchesterConsultant Physician, Manchester Royal
Infirmary, Manchester, UK.Professor of Medicine, University of Miami,
Miami, Fl, USA
AN EXPERT
‘An expert is someone who comes a long way
- and brings slides’
Henry Miller
Henry Miller
A SPECIALIST
‘A Specialist is a man who knows more and more about less and less’
William Mayo
‘Mind like parachute –Does not work if not open.’
Charlie Chan
Diabetic foot care is the PITS:-
PreventionIdentificationTreatmentService
THE DIABETIC FOOT: Two decades of progress
1986: First Malvern Diabetic Foot Meeting1987: Foot Council of ADA formed1991: First International Diabetic Foot Meeting1998: Diabetic Foot Study Group of EASD founded1998: Japanese and Alfadiem symposia on the foot1999: International Consensus group publishes
Guidelines on management
THE DIABETIC FOOT: no longer the Cinderella of diabetic complications
Publications listed on Medline on the diabetic foot / total diabetes publications
1979-1988: 0.7%1989-1996: 1.4%1997-2003: 2.7%
INTERNATIONAL MEETINGS ON THE DIABETIC FOOT
1991 First meeting – 250 delegates1995 Second meeting – 450 delegates1999 Third meeting – 600 delegates2003 Fourth meeting – 700 delegates
‘Diabetes itself may play an active part in the causation of perforating ulcers…….
..And it is abundantly evident that the actual cause of the perforating ulcers was a peripheral nerve degeneration
TD Pryce, 1887
Paul Brand CBE, MD, FRCS 1914-2003
• The Gift of Pain• Pain: the Gift nobody wants
• Surgeon and missionary: worked in leprosy and diabetes• He took the foot from art to science
Paul Brand Paul Brand
Paul Brand CBE, MD, FRCS 1914-2003
• THE ART: ‘Remove the patient’s shoes and socks and look at the feet’
• THE SCIENCE Classic studies of the relationship between pressure, time
and ulceration in the canine hind-limb
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
AMPUTATIONS IN DIABETES: TRENDS 1995-2000
• US data: steady increase in major amputations
• UK: 50% increase in one health care district
• Germany: no evidence of decrease
• Sweden: 78% decrease in amputations
CDC, 1997 Anonymous, 1997 Stiegler et al, 1998 Larrson et al, 1995 Trautner et al, 2001
Prevalence of Foot Ulcers and Amputationsin Diabetes
PrevalenceAuthor Yr Country Ulceration Amputation
Borssen 1990 Sweden 0.75%
Moss 1992 USA 3.6%
Kumar 1994 UK 1.4%
Carrington 1996 UK 4.8% 1.4%
Vozar 1997 Slovakia 2.5% 0.9%
Pendsey 1994 India 3.6% -
Van Rensbe 1995 S. Africa 11.2% -
U-Roven 1998 Slovenia 7.1% -
Belhadj 1998 Algeria 11.9% 6.7%
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
THE PAIN OF NEUROPATHY
‘Of a burning and unremitting character’
F W Pavy, 1887
PAINFUL NEUROPATHY
‘I don’t like peripheral neuritis - it interferes with work’
R D Lawrence, 1923
DIABETIC NEUROPATHY: PREVALENCE.
• UKPDS showed that >10% of patients had neuropathy at the diagnosis of Type 2 diabetes
• Neuropathy may be asymptomatic in over 50% of subjects.
• UK Community study of Type 2 patients (n=811), mean age 65 yrs. * 41.6% clinical evidence of neuropathy * 11% peripheral vascular disease
• Over 50% of older Type 2 patients have risk factors for foot ulceration
Kumar at al: 1994
UKPDS, 1998
Risk Factors for Neuropathy in UKPDS
Irene M Stratton, Rury R Holman, Andrew JM Boulton for the UKPDS group
Background to UKPDS• A multicentre, randomised clinical trial of therapies
in patients with newly diagnosed Type 2 diabetes• 5,102 subjects, mean age 53 years • Trial period 1977-1997• Recruitment ended in 1991 with main study results
in 1998• No sustained difference was seen in indices of
neuropathy between allocated treatment policies
Measures of neuropathy• Patients were assessed at entry to the study,
and then every three years for:-• vibration perception threshold (VPT)• absence of one or both ankle reflexes• erectile dysfunction (ED)
Aims
• To examine prevalence and incidence of new neuropathy we examined:-
• Age• Gender• HbA1c• Height• Waist circumference• Alcohol consumption• Smoking status• Weight
Vibration Perception Threshold
• Biothesiometer used to assess VPT at the lateral malleoli and at apex of great toes
• Abnormal VPT defined here as mean value for great toes >25 volts
Relative risk for VPT in great toes >25
12.8% prevalence at diagnosis______________________________________________________________________________________________________________________________________________________
__________
Age (per 5 years) 1.89 (1.73 to 2.07)Height (per 5 cm) 1.40 (1.32 to 1.50)Waist (per 5 cm) 1.05 (1.01 to 1.10)13.3% incidence at 12 years______________________________________________________________________________________________________________________________________________________
__________
Age (per 5 years) 1.58 (1.44 to 1.73)Female 0.56 (0.44 to 0.70)HbA1c (per 1%) 1.07 (1.01 to 1.14)
Years from entry
Age at entry
VPT in great toes >25by age
010203040506070
0 3 6 9 12
Pro
porti
on w
ith e
vent
(%)
<50 50-59 60+
Point prevalence at 12 years 37%
Conclusions• The risk factors for these 3 indices of neuropathy
were similar for prevalent cases at diagnosis and for subsequent incident cases
• For prevalence the most important risk factor was age, but HbA1c, height, waist circumference and alcohol were also significant
• For incidence age was the most important factor, again height, HbA1c and measures of obesity were important
• Twelve years from diagnosis 71% of men and 51% of women have at least one of these indices of neuropathy
Does Neuropathy Lead to Ulceration? A Prospective
Study
– 469 diabetic patients screened in 1988– Vibration perception assessed by
biothesiometry– All foot ulcers recorded
Young et al, Diabetes Care 1994;17:557
Biothesiometer
Prospective Foot Ulcer Study
Results — Foot Ulcers
VPT<15 VPT 16-24 VPT>25
Total ulcers 1988-92 6 2 41Risk per patient 2.9% 3.4% 19.6%Risk/patient/year 0.7% 0.9% 4.9%
Causal Pathways for Foot Ulceration
• Neuropathy most important component cause (78%)
• Critical triad: neuropathy, deformity, and trauma present in 63%
• Ischemia component cause in 35%• >80% of ulcers potentially preventable
Reiber, Vileikyte et al, 1999.
The Most Common Causal Pathway to Incident Diabetic
Foot Ulcers
FOOTWEAR
• Controlled evidence for reduction of recurrent ulceration
• evidence for footwear as part of multidisciplinary approach
Uccioli et al, D.Care 1995; 18: 1376 Dargis et al, D. Care 1999; 22: 1428 Faglia et al, D. Care 2001; 245: 78
Predicting Neuropathic Foot Ulcer Risk
• North West Diabetes Foot Care Study (NWDFCS)
• Population-based prospective study in NW UK – 6 health-care districts
• 16,000 patients included in total • First study on 9,710 diabetic patients Abbott et al, Diabetic Med 2002;19:377
NWDFCS: THE NDS
• 3 sensory modalities Vibration (128 Hz tuning fork – hallux) Pin-prick (Neurotip): dorsal distal hallux Hot/cold rods : dorsal distal hallux ALL: normal = 0, abnormal = 1 Ankle reflex: normal = 0, absent = 2,
reinforcement = 1 MAX TOTAL 5 each leg: =10
Abbott et al, 2002
NWDFCS: Results
• 9710 diabetic patients followed for 2 years• 291 ulcers developed: male to female: 1.6:1.0• NDS best baseline predictor NDS < 6: 1.1% annual ulcer incidence NDS > 6: 6.3% annual ulcer incidence
Abbott et al, 2002
Foot Pressure Studies in Diabetic Neuropathy
• High foot pressures associated with first and recurrent plantar neuropathic ulcers
• Foot Pressure abnormalities precede the appearance of neuropathy
• High foot pressures predict ulcers • Plantar callus associated with high pressure
and predicts ulcer formation Boulton et al, 1983, 1984, 1985,1986. Veves et al, 1992. Murray et al, 1996
Semi-Quantitative Foot Pressure Assessment
• Podotrack (PressureStat): a dynamic pressure print map system
• Inexpensive, easy to use in clinic or at home• Validated by comparison with optical
pedobarograph• All high pressure sites correctly identified by
trained observers
Van Schie et al: Diabetic Med 1999;16:154
‘Coming Events cast their shadows before.’
Thomas Campbell
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
Reducing Foot Pressures• Orthoses• Padded Hosiery• Removing callus• Footwear• Surgery• Injected liquid silicone Lavery et al, 1998 Veves et al, 1989, 1990 Young et al, 1992 Murray et al, 1996 Van Schie et al, 2001, 2002
Diabetic Foot 2000
• First randomized controlled trial• Podosil/saline injected under callus
at high pressure areas• Podosil: Increased plantar tissue
thickness: reduced pressures• This treatment may reduce ulcer
rates in high risk patientsVan Schie et al, Diabetes Care
2000;23:634
New TreatmentDoes injected liquid silicone reduce ulcer risk?
Silicone Injection in the High Risk Diabetic Foot
Diabetic Foot Ulcer Prevention
• Who responds best to silicone?• Podosil: Increased plantar tissue
thickness greatest in those with highest baseline foot pressure
• Those at highest risk of foot ulceration most likely to benefit from silicone injection.
Van Schie et al, Wounds 2002;14:26
Potential New TreatmentDoes injected liquid silicone reduce ulcer risk?
Diabetic Foot 2002
• Two year follow-up study• Podosil/saline injected under callus
at high pressure areas• Two year fu: pressure reduction
effects of ILS reduced: plantar tissue thickness remained increased
• This suggests that booster injections may periodically be required.
Van Schie et al, Arch Phys Med Rehabil 2002;83:919-923
Injected Liquid Silicone (ILS)
Does silicone’s pressure reducing effect last?
Classification of Diabetic Foot Ulcers
• Wagner Grades: 0-5: classical, most frequently quoted
• San Antonio: Wagner Grades and staging for ischaemia/infection
• Nottingham S(AD), SAD system• King’s College SSS: Stages 1-6
Armstrong et al, 1998Jeffcoate et al, 1999
Foster et al, 2000
UT Diabetic Wound Classification System
0 1 2 3
A Pre or postulcerative
lesion (epithelialized)
Superficial, not involving
tendon, capsule or bone
Penetrates to tendon or capsule
Penetrates to Bone
B INFECTION INFECTION INFECTION INFECTION
C ISCHEMIA ISCHEMIA ISCHEMIA ISCHEMIA
D INFECTION and ISCHEMIA
INFECTION and ISCHEMIA
INFECTION and ISCHEMIA
INFECTION and ISCHEMIA
Armstrong, et al, Diabetes Care, 1998Armstrong, et al, Diabetes Care, 1998
• 2 centre prospective observational study
• 194 patients followed for 6 months• Inclusion of stage (ischaemic
and/or infection) made San Antonio (UT) system a better predictor of outcome
Oyibo et al, Diabetes Care 2001;24:84
San Antonio vs Wagner classifications in wound
healing prediction
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
Factors AffectingWound Healing
Some Factors That May Influence Wound Healing
• Albumin concentration• TCpO2 concentration• Infection• Hyperglycaemia• Cytokine imbalance• Protease and inhibitor imbalance• Psychological stress
TGF- distribution in Diabetic Foot Ulcers
• TGF- 1,2 and 3 and TGF- receptor distribution in foot ulcers compared with diabetic and non-diabetic skin
• TGF- 3 expression was increased in foot ulcer biopsies
• TGF- 1 expression not increased in foot ulcers• Lack of TGF-1 upregulation may explain the
chronicity and retarded wound healing
Jude et al, Diabet Med 2002;19:440
NS DS DFU AG
TGF 1
TGF 2
TGF 3
Transforming growth factors in diabetic foot ulcers
Lack of IGF1 in Diabetic Foot Ulcers
• IGF 1 & 2 distribution in foot ulcers compared with diabetic and non-diabetic skin
• IGF 2 found throughout epidermis in all three groups
• IGF 1: absent in basal layer at ulcer edge and in fibroblasts
• Lack of expression of IGF1 may contribute to retarded wound healing
Blakytny et al, J. Pathol 2000;190:606
Matrix metalloproteinases in Diabetic Foot Ulcers
• Punch biopsies from 20 DFUs and 12 non-diabetic traumatic wounds
• MMPs 1 (x65), 2 (x6), 8(x2) and 9(x14) all increased in chronic DFUs compared to controls
• Expression of TIMP-2 decreased twofold in DFU• These findings suggest that the increased
proteolytic environment may be contributory to the chronicity of DFUs.
Lobmann et al, Diabetologia 2002;45:1011
Psychological stress and wound healing
• Anxiety/depression more common in DN: may impact adherence to off-loading Vileikyte et al, 2003
• Psychological stress slows healing of acute wounds Kiecolt-Glaser et al 1995
• Chronic stress can lead to increased IL-6 and altered MMP levels
Yang et al 2002,, Kiecolt-Glaser et al 2003
Wound Care
Factors That Enhance Wound Healing
Correct underlying condition• Control infection• Vascular reconstruction for patients with
severely compromised peripheral circulation• Adequate glycaemic control for patients
with diabetes• Off-load pressure• Maintain moist wound healing environment
Factors That Enhance Wound Healing (continued)
Adequate debridement– Removes infected and non-viable tissue– May stimulate release of endogenous
growth factors
Effect of Debridement on Healing of Diabetic Foot
Ulcers
Steed, et al. Steed, et al. J Am Coll SurgJ Am Coll Surg 1996;183:61-64. 1996;183:61-64.
100
80
60
40
20
020 40 60 10080
Patie
nts
Hea
led
(%)
Patie
nts
Hea
led
(%)
*100 µg rhPDGF-BB per gram sodium *100 µg rhPDGF-BB per gram sodium carboxymethylcellulose gel.carboxymethylcellulose gel.
Office Visits at which debridementOffice Visits at which debridementwas performed (%)was performed (%)
rhPDGF-BB*rhPDGF-BB*
PlaceboPlacebo
Common Methods to Common Methods to “Off-Load” the Foot“Off-Load” the Foot
• Bed Rest• Wheel Chair• Crutch Assisted Gait• Total Contact Casts• Felted Foam• “Half Shoes”• Therapeutic Shoes• Custom Splints• Removable Cast
Walkers
Total Contact Cast Total Contact Cast Advantages
• Forced compliance• Shortens stride
length• Decrease cadence• Reduces activity• Reduces peak
pressures
Offloading the DM Wound
Week of therapy
121086420
Cum
ulat
ive
Sur
viva
l
1.2
1.0
.8
.6
.4
.2
0.0
Device
TCC
Half Shoe
Aircast
Armstrong, et al, Diabetes Care, 2001Armstrong, et al, Diabetes Care, 2001
Activity Patterns of Persons with Diabetic Foot Ulceration: Persons with Active Ulceration may not
Adhere to a Standard Pressure-Offloading Regimen
DG ArmstrongLA LaveryHR KimbrielBP NixonAJM Boulton
From the Department of Surgery, Southern Arizona Veterans Affairs Medical Center, Tucson, AZ, USA, the Department of Medicine, Manchester Royal Infirmary, Manchester, United Kingdom, the Department of Surgery, Texas A&M University, and the Department of Medicine, University of Miami, Miami, FL, USA
Introduction
• Pressure-offloading is a critical component in treating plantar diabetic foot wounds
• Gait lab plantar pressure analysis demonstrated total contact casts (TCC) equivalent to removable cast walkers (RCW)
• Yet TCCs have been shown to be clinically superior to RCWs
Armstrong, et al, Diabetes Care, 2001 Frykberg, et al, J Foot Ankle Surg, 2000
Lavery et al, Diabetes Care, 1996
Purpose
• To evaluate the activity of persons with diabetic foot ulcerations and their adherence to their pressure offloading device.
Methods
• 20 persons were treated for UT Grade 1A neuropathic diabetic foot wounds
• All were offloaded utilizing a removable cast walker (RCW)
• Total activity was recorded (measured in activity units or steps per day) taken on a waist-worn computerized accelerometer
• We subsequently correlated this to activity recorded on a RCW-mounted accelerometer, which was not readily accessible to the patient
Results
• There were a mean 1219.1 ± 821.2 activity units (steps) taken per patient per day
• Patients logged significantly more daily activity units with the protective removable cast walker off than with it on (873.7 ± 828.0 vs. 345.3 ± 219.1, p = 0.01)
• This amounts to only 28% of total daily activity recorded while patients were wearing their removable cast walker
* p = 0.01
Activity Data: Waist vs. RCW
Conclusion
Armstrong, et al, J Amer Podiatr Med Assn, 2002Armstrong, et al, J Amer Podiatr Med Assn, 2002
• Modify RCW to make it less easily removable– “Instant” total contact cast
‘Instant Total-Contact Cast’ vs TCC: controlled trial
• TCC ‘gold standard’ but labor-intensive, expensive and time-consuming
• 2 trials in progress• a): TCC vs Instant TCC • b): Instant TCC vs Cast walker Boulton and Armstrong , 2003
‘Instant Total-Contact Cast’ vs TCC: controlled trial
• Randomized controlled trial: 38 plantar neuropathic ulcer patients randomized to instant or regular TCC
• No differences in healing times observed• Instant TCC quicker to apply and cheaper for the
duration of treatment• Any center can apply instant TCC without casting
experience• This treatment could revolutionize the management
of plantar neuropathic ulcers Katz et al , Diabetes 2004 (In press)
Studies of new therapies for neuropathic foot ulcers: time for a paradigm shift?
• Why have so many trials of dressings and other new therapies failed?
• Few if any have attended to offloading• Conclusions: we propose that all future trials
of therapies for plantar neuropathic ulcers should have standardized offloading in all treatment groups
Boulton and Jude, 2002,
Boulton and Armstrong, 2003, 2004
The effect of pressure relief on the histopathology of
diabetic foot ulcers• Randomized trial of patients with chronic
plantar diabetic neuropathic ulcers • Group A: TCC for 20 days then ulcerectomy
Group B: Ulcerectomy • Histological changes compared between the
two groups
Piaggesi et al, 2002, 2003
Histological Results
Hyperkeratosis 1.8 2.8 p<0.002
Fibrosis 1.8 2.8 p<0.007
Capillaries 2.5 0.5 p<0.001
Inflammation 1.1 3.0 P<0.001
Granulating 2.8 0.2 p<0.001
Effective offloading: histologic evidence
Piaggesi, et al, Diabetes Care, 2003Piaggesi, et al, Diabetes Care, 2003
Removable offloadingRemovable offloading Irremovable offloadingIrremovable offloading
The effect of pressure relief on the histopathology of diabetic
foot ulcers:Conclusions
• Pressure not only has a direct effect on the ulcer but also supports the chronic inflammation
• After pressure relief, the diabetic foot ulcer in many ways resembles an acute wound
• Prolonged repetitive pressure contributes to the chronicity of diabetic neuropathic foot ulcers
Piaggesi et al, 2002, 2003
Summary
• Wound healing in diabetes is impaired• Multiple factors are impaired in diabetic
wound healing• Cellular differences noted between
acute and chronic wound healing• Failure to offload pressure from plantar
neuropathic ulcers is a major contributory factor in ulcer chronicity
The future….
• Better understanding of the wound healing process in diabetes is needed
• Possibly cocktail of GFs / TIMPs?• Gene expression in chronic wound
healing• Gene therapy of wound healing in the
not too distant future?
The future….
• Role of bone marrow-derived cells? Preliminary evidence suggests that they can lead to dermal rebuilding
Badiavas & Falanga, 2003
• Role of Oestrogen? Oestrogen can enhance wound healing, possibly through
down-regulation of macrophage MIF
Ashcroft et al 2003 • Role of Androgens? Testosterone inhibits cutaneous wound healing response
in males Ashcroft & Mills 2002
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
‘To live in one land is captivity’
J. Donne
S. America
Save the diabetic foot project
Brasília, Brazil1992-2002
(A ten year educational approach to make
professionals concerned about foot problems and motivate the implementation of foot
clinics)
Pedrosa et al, Curr Diab Rep 2004
Diabetic Foot Clinics:
Implementation in Brazil -
1992 Brasília
Diabetic Foot Clinics* 1992/2001
Implemented - 34In implementation – 10
Total = 44
* outpatient basis
0
1
2
3
4
5
6
7
8
1992 1993 1994 1995 1996 1997 1998 1999 2000
DM - FemaleDM - Male
Major amputation (1992/2000)
Female: 2.67 1.72
Male: 1.11 0.71ns
Rate reduction (92-94 / 98-00)
Female = 71,42%
Male = 50%
For one mistake made for not knowing, ten mistakes are made for not looking.
J A Lindsay
“Before I came to this lecture, I was confused.
After hearing it I am still confused, but on a higher level”
Enrico Fermi
“...It ought, however, to be remembered, that more credit is due to the surgeon who saves one limb, than to he who amputates twenty.”
Edinburgh Med Surg J. 1805;1:187-193.
Who Rules the World?
‘ Do not follow where the path may lead,
go instead where there is no path, and leave a trail ’
Anon
Inferior physicians treat the full-blown diseaseGood physicians treat the
disease before it appearsSuperior physicians prevent the disease
Chinese proverb
I hear and I forgetI see and I rememberI do and I understand
Chinese proverb
‘The surest way not to fail is to be determined to succeed’
R. Sheridan
‘If you always do what you always did..
You will always get what you always got
Liam Donaldson
Success consists of going from failure to failure – without loss of enthusiasm
Winston Churchill
‘Prediction is always difficult – especially when it concerns the future.’
Wilde
The old believe everything
The middle-aged suspect everything
The young know everything
Oscar Wilde
The truth is rarely pure and never simple
Oscar Wilde
An ulcer is only a symptom of an underlying diathesis
Swartz, 1910
International Guidelines on the Outpatient Management of
Patients with Peripheral Neuropathy
Annual Review of the Diabetic Patient
• Should include:– Patient history
• Age diabetes, lifestyle,social circumstancessymptoms
– Foot examination• Skin status, sweating,
infection, blistering,joint mobility, gait,shoes
• Tests– Pin prick test– Light touch– Vibration test– Pressure perception– Ankle reflex
I marvel that society would pay a surgeon a large sum of money to remove a person’s leg — but nothing to save it.
George Bernard Shaw
ConclusionConclusion“If you don’t know where you’re
going, you’ll end up someplace else.” -Yogi Berra
“The art of life is the art of avoiding pain; and he is the
best pilot, who steers clearest of the rocks and shoals with
which it is beset.”
Thomas Jefferson
Use of Apligraf (Graftskin) in diabetic foot ulcers
• Randomized trial in 208 patients• Graftskin vs saline gauze + standard
treatment• 56% (Graftskin) vs 38% (control)
healing (p=0.004)• Time to closure 65 vs 90 days• Graftskin is a useful adjunct to best
standard care
Veves, Falanga, Armstrong, Sabolinski, Diabetes Care, 2001
A Study of Promogran in Diabetic foot ulceration
• Randomized, 11 centre trial: 276 subjects, neuropathic plantar ulcers, 12 week study
• Promogran vs. moistened gauze• Offloading constant in each centre, but
technique ‘left to individual’ • Results: 37% Promogran healed vs 28%: ns• Conclusions: Promogran safe and may be
useful for neuropathic ulcers! Veves et al, Arch Surg 2002;137:822
Results
• 30% of the patients in the study recorded more daily activity units while wearing the device (best behaved)– still only wore the device for a total of 60%
of their total daily activity
Camillo Golgi, 1898
• On the structure of nerve cells• On the structure of the nerve cells of the
spinal ganglia
Golgi, Arch Ital Biol, 1898
PAIN
‘I shall never be free until I can feel pain’
Leprosy patient in Madras: cited by Dr Paul Brand
‘If I were to choose between pain and nothing ….. I would choose pain’
William Faulkner
InflammationInflammation Proliferation/Proliferation/RegenerationRegeneration RemodellingRemodelling
WoundWoundHealingHealing
Phases of Wound Healing
Inflammation Phase
InjuryInjury
Clot FormationClot Formation(platelet aggregation)(platelet aggregation)
Release of chemotactic agentsRelease of chemotactic agents(platelet degranulation)(platelet degranulation)
Orderly recruitment of cellsOrderly recruitment of cellsinto wound siteinto wound site
Cell Influx Into Wound Site1
1. Pierce, et al 1. Pierce, et al J Cell BiochemJ Cell Biochem 1991;45:319- 1991;45:319-326326
NeutrophilsNeutrophils
MacrophagesMacrophages
FibroblastsFibroblasts
00 22 44 66 1414 2828 4242
Days Post-InjuryDays Post-Injury
88 1010
Wound Healing CascadeEarly CascadeEarly Cascade Late CascadeLate Cascade
PMNsPMNs
MacrophagesMacrophages
FibroblastsFibroblasts
Granulation TissueGranulation Tissue
Wound StrengthWound Strength
AutocrineAutocrine
AutocrineAutocrine
GFs PDGF TGF-ß1GFs PDGF TGF-ß1
PDGF-AA TGF-ß1PDGF-AA TGF-ß1
Procollagen 1Procollagen 1Extracellular MatrixExtracellular Matrix
55 1010 151500
WoundingWounding ((DaysDays))
CONCLUSIONS
• Possible future studies with higher doses
• Use of oral bisphosphonates?• Earlier diagnosis essential• Better diagnostic markers• Do not forget the words of Dr Jean-
Martin Charcot ……………………….
CHARCOT NEUROARTHROPATHY
How often have I seen persons, not yet familiar with this arthropathy,
misunderstand its real nature, and wholly preoccupied with the local affection, even absolutely forget that behind the disease of the joint there was a disease far more important in character and which really
dominated the situation J M Charcot 1881
Chronic Non-healing Wounds
• Chronic non-healing wounds occur when the normal healing process is compromised
• Ultimately, chronic wounds may fail to heal because of decreased growth factor activity or increased protease activity, or both
Roles of Growth Factors in Wound Healing
• All three phases of wound healing• Chemotaxis• Mitogenesis• Stimulate angiogenesis• Influence synthesis and degradation
of extracellular matrix• Influence synthesis of other
cytokines and growth factors
Nitric oxide in wound healing
• NO is important in the wound healing Moncada 1991, Schaffer 1997
• Reduced NO production may impair wound healingSchaffer 1997, Boykin 1999
• NO and other nitrogenous free radicals (superoxide, peroxynitrite) cause tissue destructionRadi 1991, Beckman 1990
Nitric Oxide Synthase and Arginase in Diabetic Foot Ulcers
• L Arginine metabolized by NO synthase or Arginase
• Enzyme activity measured in foot ulcers, diabetic and normal skin
• NO synthase and Arginase activities increased in foot ulcers. TGF beta 1 decreased in foot ulcers
• These findings could explain impaired healing: ? Arginase effect on callus
Jude et al, Diabetologia 1999;42:748
Adjunctive Wound Healing Modalities
• Bioengineered Tissue• Growth Factors• Hyperbaric Oxygen• Vacuum-assisted therapy• Larvatherapy• Antibiotic-impregnated beads
“In God we trust.
…all others must show data”
anon
Cultured Human Dermis (Dermagraft)
31.738.5
50.8
0
10
20
30
40
50
60
Control (n =126)
CulturedHuman Dermis(n = 109)CulturedHuman DermisTR (n = 61)
% H
ealed in 12 %
Healed in 12
Weeks
Weeks
Pollack,et. al. Wounds, 1997Pollack,et. al. Wounds, 1997
MANCHESTERLoretta VileikyteCaroline AbbottFrag AbouaeshaGillian AshcroftAnne CarringtonPeter CavanaghCuong DangMark FergusonDevaka FernandoNicky JacksonEd JudeEvangelos KatoulisAnn Knowles
Sudhesh KumarRayaz MalikEwan MassonSam OyiboY PrasadAnne RoscoePeter SelbyNick TentolourisDavid TomlinsonSteve TomlinsonCarine Van SchieAris VevesMatthew Young
United Kingdom SHEFFIELDJohn WardBill ArmstrongRick BettsChris FranksColin HardistyGraham KnightPaul NewrickJohn ScarpelloSolomon Tesfaye
ELSEWHEREPaul BakerNish ChaturvediHenry ConnorMollie DonohoeMike EdmondsAli FosterSimon PagePK ThomasBob Young
USA
MIAMIJay SkylerJohn BowkerRick CutfieldF Collado-MesaB Miranda-PalmaMark MizelJay Sosenko
ELSEWHEREDavid ArmstrongPeter CavanaghLarry HarklessLarry LaveryBen LipskyMark PeyrotGary PittengerGayle ReiberRichard RubinJan UlbrechtArthur Vinik
THE WORLDBELGIUMKristien Van AckerBRAZILHermelinda PedrosaGERMANYDan ZieglerGREECENicolas KatsilambrosEvangelos KatoulisChristos ManesNicolas TentolourisDimitris Voyatzaglou
ITALYGuido MenzingerLuigi UccioliLITHUANIAVytas Dargis Vladimir PetrenkoNETHERLANDSKarel BakkerAUSTRALIAJonathan Shaw
DifferenDifferences ces in cellular infiltrate in cellular infiltrate between acute and chronic between acute and chronic
wounds?wounds?• Cross-sectional study in acute wounds
vs. venous and diabetic ulcers• ECM molecules and cellular infiltrates
compared• Prolonged presence of ECM
molecules noted in dermis of chronic ulcers
• Decreased CD4 T cells, increased B cells and macrophages in chronic ulcers
Loots et al, J. Invest Dermatol, 1998;111:850
““Epidemiology Epidemiology is what you do is what you do when you run out when you run out of ideas”of ideas”
J.D.WardJ.D.Ward
Ethnicity and foot ulceration and amputations
• Diabetic foot ulcers much less common amongst Indian sub-continent Asians in the Manchester area
Toledano et al, 1995
• Amputations 4x more common in Europids compared to Asians in NW UK
Chaturvedi, Abbott et al, Diab Med 2002;19:99
• Ethnicity and Diabetic Neuropathy Ongoing study in NW UK supported by Diabetes UK
Abbott, Chaturvedi et al, 2004
DIABETIC NEUROPATHY
‘PAIN – God’s greatest gift to mankind’
Paul Brand
Future MeetingsFuture Meetings2nd International Meeting on Chronic
Wounds: WUWHS meeting, Paris, France, July 8 – 13th 2004
Cleveland Clinic International Meeting on the Diabetic Foot, 2005
11th Malvern Diabetic Foot Meeting,May 2006
The Diabetic Foot
• Epidemiology• Causal pathways• Reducing foot pressures• Charcot Foot• Wound healing• International perspective
Charcot Foot
• Common in neuropathic patients• frequently mis-diagnosed• treatable if diagnosed early• suspect in neuropathic patient with
warm, swollen foot• AN UPDATE 2004
• Neuropathy - sensory/autonomic• Increased blood flow• Arteriovenous shunting• Reduced BMD / Osteoporosis• ?Osteoclast activation/bone resorption
Pathogenesis
• Trauma
1. To reduce disease activity
2. To achieve a stable joint
3. To reduce deformity
Treatment Goals
Treatment
• Casting• Non-steroidals• Immobilisation• Radiotherapy• Extra-depth shoes• Pharmacotherapy• Surgery
Pamidronate in Charcot
• Open-labelled trial• 6 patients with acute CNA• Pamidronate 60 mg 2-weekly x6• At each time point:
- Skin temps measured (Mikron infrared thermometer)- Alkaline phosphatase Selby Diabetic Med 1994
0
1
2
3
4T
empe
ratu
re d
iffer
ence
(°C
)
Temperature difference between affected and intact foot
2 4 10 126 8Basal
* * * * *
Weeks of therapySelby Diabetic Med 1994
-30-25
-20-15-10
-5
05
Basal 2 4 6 8 10 12
Weeks of therapy
%ag
e ch
ange
in A
PPercentage change in plasma alkaline
phosphatase
Selby Diabetic Med 1994
Randomised double-blind trial of Pamidronate in
Diabetic Charcot Arthropathy
Jude et al Diabetologia 2001;44:2032
Exeter
London
NottinghamManchester
-3
-2
-1
0
1
0 2 4 6 8 10 12 24 36 52
Weeks
Tem
pera
ture
diff
eren
ce (°
C)
Active
Placebo
Effect of Pamidronate on disease activity
0
5
10
15
20
25
2 4 6 8 10 12 24 36 52
Weeks
BSA
P (u
/l)Effect of Pamidronate on Bone Specific
Alkaline Phosphatase
Active
Placebo* * * * *
0
2
4
6
8
0 2 4 6 8 10 12 24 36 52
Weeks
DPD
(nM
/mM
)
* *
Active
Placebo
Effect of Pamidronate on DPD crosslinks
Discussion
• Bone turnover markers are increased in Charcot arthropathy
• Immobilisation is effective in reducing Charcot activity
• Pamidronate is effective in reducing both disease activity and bone turnover markers
Peak pressure 2nd MTH
0
2
4
6
8
10
12
14
0 500 1000 1500 2000
Peak plantar pressure (kPa)
Plan
tar
tissu
e th
ickn
ess (
mm
) r = - 0.53 (p<0.001)
Conclusions• Plantar tissue thickness measurement is a useful
alternative method to study patients at risk of foot ulceration
• Follow up of these patients will point to the importance of these measurements in clinical practice
Abouaesha et al, Diabetes Care 2001;24:1270
The ‘Instant Total-Contact Cast’
• TCC ‘gold standard’ but labor-intensive, expensive and time-consuming
• Why not use cast-walker or Scotchcast boot made ‘irremovable’
• Removable device wrapped with cohesive bandage (Coband) or plaster
• The device can then be re-attached weekly after removal of bandage and wound inspection
• Conclusions: an ‘instant’ or ‘poor man’s’ TCC Armstrong et al, JAPMA, 2001
Why are trials of removable devices so disappointing?
• When given specialist footwear, only 20% of patients report wearing regularly
• DH walker offloads as well as TCC• DH walker worn for only 28% of daily activity• Conclusions: Despite all good intentions,
offloading devices are used for a minority of daily walking activity
Knowles & Boulton 1996, Lavery et al, 1996 Armstrong et al, 2003
INTERNATIONAL MEETINGS ON THE DIABETIC FOOT
DECEMBER 1988, Howard Johnson 57 Hotel, Boston, Mass, USA
Meeting on Diabetic Foot organized by Bob Frykberg.
In Attendance: Karel Bakker, John Dooren, Jan Rauwerda, Andrew Boulton
‘I don’t like peripheral neuritis – it interferes with work
RD Lawrence, 1923
Neuropathy and Foot Ulceration: Prospective Study
– 169 patients, 22 controls: Manchester, UK– Spectrum of neuropathic deficits. Six year follow
up– 37% ulcers, 11% amputation, 18% died– MNCV best predictor of ulcers, arterial calcification
& PPT, amputation; MNCV,Creatinine & TcPO2 predicted mortality
CONCLUSION: MNCV is the best surrogate endpoint for end-stage neuropathy
Carrington et al, Diabetes Care 2002;25:2010-2015